T
Thrombolytic Science International
TSI is developing a novel therapeutic regimen that will lower the debilitating effects of a #stroke and save lives
About Thrombolytic Science International
Thrombolytic Science (TSci) is a pioneering biopharmaceutical company focused on transforming the treatment of thrombotic diseases, such as ischemic stroke and heart attack. TSci operates in the healthcare and pharmaceutical market, primarily serving patients experiencing acute thrombotic events. The company's core product is a novel intravenous biotherapy, HisproUK, designed to restore blood flow quickly and safely after the onset of a stroke or heart attack. This dual regimen therapy has shown promising results in clinical trials, including Phase 1 and Phase 2 studies, confirming its safety and efficacy.
TSci's business model revolves around the development and commercialization of its innovative thrombolytic therapies. The company generates revenue through the sale of its biotherapeutic products to healthcare providers and institutions. By focusing on early intervention and rapid treatment, TSci aims to improve patient outcomes and reduce the long-term healthcare costs associated with thrombotic diseases.
The market for thrombolytic therapies is significant, given the high incidence of stroke and heart attack globally. TSci's approach of taking the drug to the patient, rather than the patient to the drug, represents a paradigm shift in the treatment of these conditions. This strategy not only enhances patient access to life-saving treatments but also has the potential to set new standards of care in the industry.
Source: Dealroom company dataNews
Open roles
Thrombolytic Science International in the Cambridge ecosystem
The Thrombolytic Science International office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Thrombolytic Science International on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Thrombolytic Science International on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.